Canadian Genomics Innovation Showcase

​Join the Consulate General of Canada in Boston for an exclusive program showcasing the strength and momentum of Canada’s genomics and life sciences ecosystems.

​During the program Genome Canada will highlight Canada’s national capabilities across genomics, AI, and precision medicine, followed by a curated series of rapid-fire presentations from innovative Canadian companies and organizations, each delivering concise, high-impact pitches designed to spark collaboration, investment, and partnership opportunities.

​Following the presentations, I hope you will be able to join us for a casual networking reception with founders, scientists, investors, and ecosystem leaders from both Canada and Boston.

​Come join the Canadian Consulate and these Innovative companies:

​BioAro Inc.
BioAro Inc. is a Canadian precision health company delivering personalized medicine through genomic and multi‑omics testing. Based in Calgary, it provides sequencing, microbiome analysis, pharmacogenomics, and AI‑driven insights to support prevention, longevity, and optimized treatment. BioAro integrates lab services, digital platforms, and clinical support to turn complex data into actionable healthcare decisions.

​Epiloid Biotechnology
Epiloid Biotechnology develops therapies for epilepsy and neurological disorders, focusing on disease‑modifying approaches to reduce seizures and improve long‑term outcomes. Combining neuroscience with targeted drug development, it addresses unmet needs in drug‑resistant epilepsy.

​Genome Canada
Genome Canada is a federally funded non‑profit catalyzing genomics research and innovation nationwide. Working with regional centres, it supports large‑scale initiatives across health, agriculture, sustainability, and the bioeconomy, translating research into policy, commercialization, and societal impact.

​Genome Québec
Genome Québec is a non‑profit and regional centre of Genome Canada advancing genomics research and adoption. It funds projects, operates genomic platforms, and supports education, helping integrate genomics into healthcare, agriculture, and environmental management.

​Incisive Genetics Inc.
Incisive Genetics develops genetic medicines using a proprietary non‑viral gene editing platform. Known for allele‑selective CRISPR therapies for Huntington’s disease, it aims to edit mutations while preserving healthy genes. Its lipid nanoparticle system enables repeat dosing and safer in vivo delivery.

​i-RNA Corporation
i RNA Corporation develops RNA‑based therapeutics for cancer and other diseases. It focuses on RNA interference and modulation to precisely regulate gene expression while minimizing off‑target effects, improving the stability and clinical potential of RNA medicines.

​Nimble Science Ltd.
Nimble Science develops technologies for human microbiome research, including non‑invasive gastrointestinal sampling that goes beyond stool analysis. Its platform improves microbiome data collection for clinical research, diagnostics, and therapeutic development.

​Performance Plants Inc.
Performance Plants provides gene editing technology licensing and services for medical and agricultural use. Its proprietary system, distinct from Cas9, is highly efficient and supported by strong patents. Flexible licensing enables cost‑effective in‑house development.

​PhenoTips
PhenoTips offers a secure genomic health record platform for clinical and research settings. It enables structured phenotypic and genetic data analysis using standards like HPO and integrates with EHR systems to improve diagnostics and patient care.

​ProteinQure
ProteinQure is a clinical‑stage biotech using AI and molecular simulation to design peptide therapeutics. Its platform develops targeted drug conjugates for tissue‑specific delivery, improving efficacy and reducing side effects, with oncology programs in clinical trials.

​QurCan Therapeutics
QurCan Therapeutics develops nanoparticle delivery technologies for RNA and biologics. Its TERP platform enables tissue‑selective, non‑viral delivery, including to the brain, advancing treatments for CNS diseases and cancer.

​RJH Biosciences
RJH Biosciences specializes in non‑viral transfection reagents and nucleic acid delivery systems. It supports mRNA, siRNA, CRISPR, and DNA research while advancing platforms for therapeutic use across gene, cell, and RNA therapies.

​Scispot
Scispot provides a unified “LabOS” platform integrating ELNs, sample tracking, data management, automation, and AI analytics. It helps labs eliminate data silos, improve compliance, and accelerate research through connected workflows.